The
coronavirus disease 2019 (COVID-19) pandemic continues to ravage
the world, with many hospitals overwhelmed by the large number of
patients presenting during major outbreaks. A rapid triage for COVID-19
patient requiring hospitalization and intensive care is urgently needed.
Age and comorbidities have been associated with a higher risk of severe
COVID-19 but are not sufficient to triage patients. Here, we investigated
the potential of attenuated total reflectance Fourier-transform infrared
(ATR-FTIR) spectroscopy as a rapid blood test for classification of
COVID-19 disease severity using a cohort of 160 COVID-19 patients.
A simple plasma processing and ATR-FTIR data acquisition procedure
was established using 75% ethanol for viral inactivation. Next, partial
least-squares-discriminant analysis (PLS-DA) models were developed
and tested using data from 130 and 30 patients, respectively. Addition
of the ATR-FTIR spectra to the clinical parameters (age, sex, diabetes
mellitus, and hypertension) increased the area under the ROC curve
(C-statistics) for both the training and test data sets, from 69.3%
(95% CI 59.8–78.9%) to 85.7% (78.6–92.8%) and 77.8%
(61.3–94.4%) to 85.1% (71.3–98.8%), respectively. The
independent test set achieved 69.2% specificity (42.4–87.3%)
and 94.1% sensitivity (73.0–99.0%). Diabetes mellitus was the
strongest predictor in the model, followed by FTIR regions 1020–1090
and 1588–1592 cm
–1
. In summary, this study
demonstrates the potential of ATR-FTIR spectroscopy as a rapid, low-cost
COVID-19 severity triage tool to facilitate COVID-19 patient management
during an outbreak.